A DEDICATED biologics team has just been launched by Arrotex Pharmaceuticals, to connect prescribers and pharmacists to deliver optimal support to patients prescribed biosimilars.
According to the General Manager of Specialty Brands and Biologics, Matthew Donnison, the new biologics capability, which sits within the recently formed Arrotex Medical Services division (PD 16 Feb), aims to add value to the prescriber, community pharmacist and patient experience with Arrotex's partnered biosimilar portfolio.
"Provision of effective patient support is critical to a prescriber and community pharmacist centre of care model.
"In order to better communicate the support available to biologics patients, we required a significantly more robust patient support program to improve our patient proposition," explained Donnison.
"Based on the outcomes of our Arrotex biologics education framework, which has been available to community pharmacy for more than 18 months, we have chosen to establish a team of Patient Experience Liaisons (PELs).
"These specialist medical representatives are well positioned to both detail, and drive uptake of our patient support services available to specialist prescribers, community pharmacists and patients, including the provision of supportive counselling through device changes, and a patient's ongoing health journey."
The 14-strong PEL team should build on the existing Arrotex medical team of pharmacist biologics educators, who collectively, will support patients through the switch from originator to biosimilar devices.
"Their services will encompass patient enrolment at prescription, and will be available once an Arrotex biosimilar is dispensed," shared Donnison.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Jun 23
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Jun 23
